Biogen and Denali Discontinue BIIB122 Development Following Phase 2b LUMA Results

Phase 2b Study Misses Primary Endpoints in Early-Stage Parkinson's Disease

Biogen and Denali Therapeutics have announced topline results from the Phase 2b LUMA clinical trial evaluating BIIB122 (DNL151), an investigational LRRK2 inhibitor for early-stage Parkinson's disease. The study did not achieve its primary or secondary efficacy endpoints, leading both companies to discontinue the development of BIIB122 for idiopathic Parkinson's disease. Denali will, however, continue its independently sponsored Phase 2a BEACON study in patients with Parkinson's disease associated with pathogenic LRRK2 gene variants.

Evaluating a Disease-Modifying Therapy

The global Phase 2b LUMA trial enrolled individuals with early-stage Parkinson's disease to determine whether BIIB122 could slow disease progression by inhibiting the LRRK2 protein, a therapeutic target linked to Parkinson's disease biology. Despite encouraging earlier clinical data, the latest study did not demonstrate meaningful clinical benefit compared with placebo.

Focus Shifts to Genetically Defined Parkinson's Disease

Although the LUMA program has concluded, Denali will continue investigating BIIB122 in the ongoing Phase 2a BEACON study involving patients who carry pathogenic LRRK2 variants. Researchers believe this genetically defined patient population may provide additional insights into the therapeutic potential of LRRK2 inhibition and help guide future precision medicine approaches.

Continuing Innovation in Neurodegenerative Research

Parkinson's disease remains an area of significant unmet medical need, with ongoing efforts focused on developing treatments that modify disease progression rather than only managing symptoms. While the LUMA outcome represents a setback for BIIB122, both companies emphasized their continued commitment to advancing neuroscience research and exploring new therapeutic strategies for neurodegenerative disorders.

Key Features

• Phase 2b LUMA study evaluated BIIB122 (DNL151)

• Investigational LRRK2 inhibitor for early-stage Parkinson's disease

• Primary and secondary study endpoints were not achieved

• Development discontinued for idiopathic Parkinson's disease

• Phase 2a BEACON study continues in LRRK2 mutation carriers

• Focus on genetically targeted Parkinson's disease research

• Collaboration between Biogen and Denali Therapeutics

• Ongoing commitment to neuroscience innovation

Applications

• Parkinson's disease clinical research

• Neurodegenerative disease drug development

• Precision medicine studies

• LRRK2-targeted therapeutics

• Clinical trial research

• Biomarker-driven drug development

• Neuroscience innovation

• Pharmaceutical research

Advancing Parkinson's Disease Research

Clinical research plays a critical role in improving the understanding of complex neurological disorders and guiding future therapeutic development. Although BIIB122 will no longer be pursued for idiopathic Parkinson's disease, the continued evaluation of LRRK2 inhibition in genetically defined patient populations may contribute valuable scientific knowledge that supports the development of future targeted treatments.